<DOC>
	<DOC>NCT00660673</DOC>
	<brief_summary>The primary objective is to provide continued access to subjects who would like to continue levodopa-carbidopa intestinal gel (LCIG), after completion of an open-label study (S187.3.003 or S187.3.004).</brief_summary>
	<brief_title>Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced PD</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa, levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>The subject should have completed participation in Study S187.3.003 or S187.3.004; and, in the opinion of the Principal Investigator, would benefit from longterm treatment with LCIG. For Canada, subjects will be allowed to participate in the S187.3.005 study with a minimum of 6 months of exposure to LCIG in the S187.3.004 study. The subject must be able to understand the nature of the study and must provide written informed consent prior to the conduct of any study related procedures. If the subject does not have the capacity to provide informed consent, full informed consent must be obtained from the subject's legally authorized representative. Consenting will be performed according to local regulations. Medical, laboratory, psychiatric, or surgical issues deemed by the investigator to be clinically significant and which could interfere with the subjects participation in the study.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>levodopa/carbidopa intestinal gel</keyword>
	<keyword>Dyskinesia</keyword>
	<keyword>Carbidopa</keyword>
	<keyword>Parkinson's Disease</keyword>
	<keyword>Severe Motor Fluctuations</keyword>
	<keyword>Levodopa</keyword>
</DOC>